Communiqués IN8bio, Inc.

Actions

INAB

US45674E1091

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,8465 ^USD	-5,87%		-4,77%	-38,66%

14/06	IN8BIO, INC. : JonesTrading Institutional Services persiste à l'achat	ZM
13/06	IN8bio, Inc. approuve les nominations au conseil d'administration	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference	24/06	AQ
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100	13/06	AQ
IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting	03/06	AQ
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024	24/05	AQ
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting	23/05	AQ
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress	14/05	AQ
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024	13/05	AQ
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	09/05	AQ
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma	30/04	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene and Cell Therapy 2024 Annual Meeting	25/04	AQ
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	24/04	AQ
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	16/04	AQ
IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	09/04	AQ
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	14/03	AQ
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	05/03	AQ
IN8bio to Present at Upcoming Investor Conferences	26/02	BU
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	14/02	AQ
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals	04/01	AQ
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	11/12	AQ
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement	11/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués IN8bio, Inc.

Actions

INAB

US45674E1091

Communiqués

Filtres